TY - JOUR
T1 - P38 gamma and p38 delta regulate postnatal cardiac metabolism through glycogen synthase 1
AU - Santamans, Ayelén M.
AU - Montalvo-Romeral, Valle
AU - Mora, Alfonso
AU - Lopez, Juan Antonio
AU - González-Romero, Francisco
AU - Jimenez-Blasco, Daniel
AU - Rodríguez, Elena
AU - Pintor-Chocano, Aránzazu
AU - Casanueva-Benítez, Cristina
AU - Acín-Pérez, Rebeca
AU - Leiva-Vega, Luis
AU - Duran, Jordi
AU - Guinovart, Joan J.
AU - Jiménez-Borreguero, Jesús
AU - Enríquez, José Antonio
AU - Villlalba-Orero, María
AU - Bolaños, Juan P.
AU - Aspichueta, Patricia
AU - Vázquez, Jesús
AU - González-Terán, Bárbara
AU - Sabio, Guadalupe
N1 - Funding Information:
G.S. is a YIP EMBO member. B.G.T. was a fellow of the FPI Severo Ochoa CNIC program (SVP-2013-067639) and currently is funded by the AHA-CHF (AHA award number: 818798). V.M.R. is a FPI fellow (BES-2014-069332) and A.M.S. is a fellow of the FPI Severo Ochoa CNIC program (BES-2016-077635). This work was funded by the following grants: to G.S.: funding from the EFSD/Lilly European Diabetes Research Programme Dr Sabio, from Spanish Ministry of Science, Innovation and Universities (MINECO-FEDER SAF2016-79126-R and PID2019-104399RB-I00), Comunidad de Madrid (IMMUNOTHERCAN-CM S2010/BMD-2326 and B2017/BMD-3733) and Fundacion Jesus Serra; to P.A.: Ayudas para apoyar grupos de investigacion del sistema Universitario Vasco (IT971-16 to P.A.), MCIU/AEI/FEDER, funding from Spanish Ministry of Science, Innovation and Universities (RTI2018-095134-B100); Excellence Network Grant from MICIU/AEI (SAF2016-81975-REDT and 2018-PN188) to PA and GS; to J.V.: funding from Spanish Ministry of Science, Innovation and Universities (PGC2018-097019-B-I00), the Instituto de Salud Carlos III (Fondo de Investigacion Sanitaria grant PRB3 (PT17/0019/0003-ISCIII-SGEFI/ERDF, ProteoRed), and "la Caixa" Banking Foundation (project code HR17-00247); to J.P.B.: funding from Spanish Ministry of Science, Innovation and Universities (PID2019-105699RB-I00, RED2018-102576-T) and Escalera de Excelencia (CLU-2017-03); to J.A.E.: funding from Spanish Ministry of Science, Innovation and Universities MINECO (RED2018-102576-T, RTI2018-099357-B-I00), CIBERFES (CB16/10/00282), and HFSP (RGP0016/2018). RAP (XPC/BBV1602 and MIN/RYC1102). The CNIC is supported by the Ministry of Science, Innovation and Universities and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Publisher Copyright:
© 2021 Public Library of Science. All rights reserved.
PY - 2021/11
Y1 - 2021/11
N2 - During the first weeks of postnatal heart development, cardiomyocytes undergo a major adaptive metabolic shift from glycolytic energy production to fatty acid oxidation. This metabolic change is contemporaneous to the up-regulation and activation of the p38 gamma and p38 delta stress-activated protein kinases in the heart. We demonstrate that p38 gamma/delta contribute to the early postnatal cardiac metabolic switch through inhibitory phosphorylation of glycogen synthase 1 (GYS1) and glycogen metabolism inactivation. Premature induction of p38 gamma/delta activation in cardiomyocytes of newborn mice results in an early GYS1 phosphorylation and inhibition of cardiac glycogen production, triggering an early metabolic shift that induces a deficit in cardiomyocyte fuel supply, leading to whole-body metabolic deregulation and maladaptive cardiac pathogenesis. Notably, the adverse effects of forced premature cardiac p38 gamma/delta activation in neonate mice are prevented by maternal diet supplementation of fatty acids during pregnancy and lactation. These results suggest that diet interventions have a potential for treating human cardiac genetic diseases that affect heart metabolism.
AB - During the first weeks of postnatal heart development, cardiomyocytes undergo a major adaptive metabolic shift from glycolytic energy production to fatty acid oxidation. This metabolic change is contemporaneous to the up-regulation and activation of the p38 gamma and p38 delta stress-activated protein kinases in the heart. We demonstrate that p38 gamma/delta contribute to the early postnatal cardiac metabolic switch through inhibitory phosphorylation of glycogen synthase 1 (GYS1) and glycogen metabolism inactivation. Premature induction of p38 gamma/delta activation in cardiomyocytes of newborn mice results in an early GYS1 phosphorylation and inhibition of cardiac glycogen production, triggering an early metabolic shift that induces a deficit in cardiomyocyte fuel supply, leading to whole-body metabolic deregulation and maladaptive cardiac pathogenesis. Notably, the adverse effects of forced premature cardiac p38 gamma/delta activation in neonate mice are prevented by maternal diet supplementation of fatty acids during pregnancy and lactation. These results suggest that diet interventions have a potential for treating human cardiac genetic diseases that affect heart metabolism.
KW - Fatty-acid oxidation
KW - Storage-disease
KW - Molecular-mechanisms
KW - Mice
KW - Phosphorylation
KW - Deficiency
KW - Glucose
KW - Muscle
KW - Adult
KW - Liver
UR - http://www.scopus.com/inward/record.url?scp=85119908889&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_univeritat_ramon_llull&SrcAuth=WosAPI&KeyUT=WOS:000750903600002&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1371/journal.pbio.3001447
DO - 10.1371/journal.pbio.3001447
M3 - Article
C2 - 34758018
AN - SCOPUS:85119908889
SN - 1544-9173
VL - 19
JO - PLoS Biology
JF - PLoS Biology
IS - 11
M1 - e3001447
ER -